HCPCS Level II
J1308
Injection, famotidine, 0.25 mg
Codes near J1308
These sit next to J1308 in the CMS Level II file. All J codes
- J1303Injection, ravulizumab-cwvz, 10 mg
- J1304Injection, tofersen, 1 mg
- J1305Injection, evinacumab-dgnb, 5mg
- J1306Injection, inclisiran, 1 mg
- J1307Injection, crovalimab-akkz, 10 mg
- J1320Injection, amitriptyline hcl, up to 20 mg
- J1322Injection, elosulfase alfa, 1 mg
- J1323Injection, elranatamab-bcmm, 1 mg
- J1324Injection, enfuvirtide, 1 mg
- J1325Injection, epoprostenol, 0.5 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00338-5197-41 | Famotidine | Baxter Healthcare Corporation | 960 |
| 00641-6021-10 | Famotidine | Hikma Pharmaceuticals USA Inc. | 8000 |
| 00641-6022-25 | Famotidine | Hikma Pharmaceuticals USA Inc. | 2000 |
| 00641-6023-10 | Famotidine | Hikma Pharmaceuticals USA Inc. | 1600 |
| 25021-0753-02 | Famotidine | Sagent Pharmaceuticals | 2000 |
| 51662-1375-01 | Famotidine | HF Acquisition Co. LLC, DBA HealthFirst | 80 |
| 51662-1375-02 | Famotidine | HF Acquisition Co. LLC, DBA HealthFirst | 80 |
| 63323-0738-09 | Famotidine | FreseniUS Kabi USA, LLC | 1600 |
| 63323-0738-20 | Famotidine | FreseniUS Kabi USA, LLC | 8000 |
| 63323-0739-12 | Famotidine | FreseniUS Kabi USA, LLC | 2000 |
| 63323-0739-16 | Famotidine | FreseniUS Kabi USA, LLC | 2000 |
| 67457-0433-22 | Famotidine | Mylan Institutional LLC | 2000 |
| 67457-0448-43 | Famotidine | Mylan Institutional LLC | 1600 |
| 67457-0457-20 | Famotidine | Mylan Institutional LLC | 8000 |
| 70860-0751-02 | Famotidine | Athenex Pharmaceutical Division, LLC | 2000 |
| 70860-0753-20 | Famotidine | Athenex Pharmaceutical Division, LLC | 8000 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.